← Back to Screener
Treace Medical Concepts, Inc. Common Stock (TMCI)
Price$3.60
Value ScoreB
Growth ScoreC
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)16.64%
Price vs S&P 500 (4W)81.05%
VGM Score61.37
Market Capitalization$224.46M
All Metrics
Book Value / Share (Quarterly)$1.19
P/TBV (Annual)1.95x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)14.47%
Cash Flow / Share (Quarterly)$-0.40
Price vs S&P 500 (YTD)30.29%
Gross Margin (TTM)79.72%
Net Profit Margin (TTM)-29.44%
EPS (TTM)$-0.96
10-Day Avg Trading Volume0.61M
EPS Excl Extra (TTM)$-0.96
Revenue Growth (5Y)29.95%
EPS (Annual)$-0.93
ROI (Annual)-41.28%
Gross Margin (Annual)79.81%
Net Profit Margin (5Y Avg)-26.57%
Cash / Share (Quarterly)$0.80
Revenue Growth QoQ (YoY)-10.22%
ROA (Last FY)-30.96%
Revenue Growth TTM (YoY)-1.66%
EBITD / Share (TTM)$-0.78
ROE (5Y Avg)-49.14%
Operating Margin (TTM)-28.21%
Cash Flow / Share (Annual)$-0.46
P/B Ratio2.91x
P/B Ratio (Quarterly)1.12x
Net Income / Employee (Annual)$-131,100
EV / Revenue (TTM)1.31x
Net Interest Coverage (TTM)-22.20x
ROA (TTM)-31.39%
EPS Incl Extra (Annual)$-0.93
Current Ratio (Annual)4.31x
Quick Ratio (Quarterly)2.38x
3-Month Avg Trading Volume0.77M
52-Week Price Return-40.96%
Revenue / Employee (TTM)$460,700
Tangible BV / Share (Quarterly)$1.09
P/S Ratio (Annual)1.06x
Asset Turnover (Annual)1.12x
52-Week High$7.78
Operating Margin (5Y Avg)-25.25%
EPS Excl Extra (Annual)$-0.93
CapEx CAGR (5Y)66.07%
26-Week Price Return32.57%
Quick Ratio (Annual)2.95x
13-Week Price Return64.76%
Total Debt / Equity (Annual)0.64x
Current Ratio (Quarterly)3.58x
Enterprise Value$270.74M
Revenue / Share Growth (5Y)24.22%
Asset Turnover (TTM)1.07x
Revenue / Employee (Annual)$472,600
Inventory Turnover (Annual)1.14x
Pretax Margin (Annual)-27.74%
Cash / Share (Annual)$0.76
3-Month Return Std Dev109.39%
Gross Margin (5Y Avg)80.63%
Net Income / Employee (TTM)$-135,600
ROE (Last FY)-67.56%
Net Interest Coverage (Annual)-18.43x
EPS Basic Excl Extra (Annual)$-0.93
Receivables Turnover (TTM)6.75x
Total Debt / Equity (Quarterly)0.72x
EPS Incl Extra (TTM)$-0.96
Receivables Turnover (Annual)5.13x
ROI (TTM)-42.64%
P/S Ratio (TTM)1.08x
Pretax Margin (5Y Avg)-26.57%
Revenue / Share (Annual)$3.36
Tangible BV / Share (Annual)$1.25
Price vs S&P 500 (52W)-69.16%
Year-to-Date Return41.22%
5-Day Price Return24.46%
EPS Normalized (Annual)$-0.93
ROA (5Y Avg)-23.57%
Net Profit Margin (Annual)-27.74%
Month-to-Date Return91.16%
Cash Flow / Share (TTM)$-0.73
EBITD / Share (Annual)$-0.73
Operating Margin (Annual)-26.75%
LT Debt / Equity (Annual)0.64x
ROI (5Y Avg)-31.08%
LT Debt / Equity (Quarterly)0.72x
EPS Basic Excl Extra (TTM)$-0.96
P/TBV (Quarterly)1.23x
P/B Ratio (Annual)1.79x
Inventory Turnover (TTM)1.13x
Pretax Margin (TTM)-29.44%
Book Value / Share (Annual)$1.36
Price vs S&P 500 (13W)55.02%
Beta1.41x
Revenue / Share (TTM)$3.21
ROE (TTM)-69.50%
52-Week Low$1.17
vGradeB
gGradeC
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.28est. -0.31
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
2.55
2.55
2.50
2.50
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TMCITreace Medical Concepts, Inc. Common Stock | B | C | B | $3.60 |
| SYKStryker Corporation | C | C | D | $299.46 |
| MMM3M Company | C | F | C | $150.93 |
| BSXBoston Scientific Corp. | C | B | F | $47.98 |
| MDLNMedline Inc. Class A common stock | C | D | D | $35.75 |
| BDXBecton, Dickinson and Co. | B | C | C | $145.33 |
| DXCMDexCom, Inc. | C | B | C | $74.87 |
| RMDResMed Inc. | B | B | D | $186.44 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $316.30 |
| SOLVSolventum Corporation | C | D | C | $75.84 |
| PENPenumbra, Inc. | F | C | C | $318.95 |
About
Treace Medical Concepts develops and commercializes the Lapiplasty 3D Bunion Correction procedure, a patented surgical solution for treating bunion deformities. The procedure addresses the underlying cause of bunions across all planes of deformity while enabling patients to return to normal activities quickly. The company markets its devices to surgeons, ambulatory surgery centers, and hospitals in the large and growing orthopedic foot surgery market.